Goel et al. have shown that CDK4/6 inhibition can also resensitize HER2-resistant breast cancer cells to trastuzumab, and that a combination of CDK4/6i abemaciclib with trastuzumab induces tumor regression in a HER2-driven breast cancer mouse model [193]. Here, CDK4 is linked to breast carcinoma.